A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model.
Dietary patterns among individuals with plasma cell disorders- opportunities for targeted interventions.
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM.
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients.
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.
Figure S3. from A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Figure S8. from A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Figure S6. from A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Data from A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Figure S7. from A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Figure S4. from A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Figure S2 from A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Figure S5. from A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Supplementary Tables S1-S22 from A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Figure S1 from A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
CD8+CD38+ T cells Identify Functional High-Risk Multiple Myeloma After Autologous Transplant: BTM CTN 0702 Correlates
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
Temporal genomic dynamics shape clinical trajectory in multiple myeloma.
Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.
Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-3
Restarting teclistamab and talquetamab after prolonged dose delay may not require re-step-up dosing.
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.
Knowledge-informed multimodal cfDNA analysis improves sensitivity and generalization in cancer detection
Knowledge-informed multimodal cfDNA analysis improves sensitivity and generalization in cancer detection
Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance.
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experience.
Robust CD4
<sup>+</sup>
CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel